Director granted 2,492 Caris Life Sciences (CAI) shares as fees

Rhea-AI Filing Summary

Caris Life Sciences director David Paul Fredrickson acquired 2,492 shares of common stock as compensation. The shares were issued on February 26, 2026 in lieu of cash payment for his 2025 board retainer fees, valued at $20.06 per share.

After this stock award, his directly held stake increased to 18,621 common shares. The number of shares granted was calculated by dividing the cash retainer earned by the 10-day average volume-weighted average price per share through February 25, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fredrickson David Paul

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		2,492	A	$20.06	18,621	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Caris Life Sciences (CAI) disclose in this Form 4?

Caris Life Sciences reported that director David Paul Fredrickson received 2,492 common shares. These were issued as stock in place of cash for his 2025 board retainer, reflecting routine equity-based director compensation rather than an open-market purchase or sale.

How many Caris Life Sciences (CAI) shares did the director receive and at what value?

The director was granted 2,492 shares of Caris Life Sciences common stock, valued at $20.06 per share. This share count was derived from his earned cash retainer using a ten-day average volume-weighted average price calculation ending February 25, 2026.

Did the Caris Life Sciences (CAI) director buy these shares on the open market?

No, the director did not buy these shares on the open market. The 2,492 shares were granted as a stock award in lieu of cash board retainer fees, based on a formula using the ten-day average trading price through February 25, 2026.

How many Caris Life Sciences (CAI) shares does the director hold after this grant?

Following the stock award, director David Paul Fredrickson directly holds 18,621 shares of Caris Life Sciences common stock. This total reflects the addition of 2,492 shares received as compensation for his 2025 board retainer instead of a cash payment.

How was the number of Caris Life Sciences (CAI) shares for the board retainer determined?

The company calculated the 2,492-share grant by dividing the director’s cash retainer earned by the ten-trading-day average of the daily volume-weighted average price per share. This averaging period extended through and included February 25, 2026 to set the conversion rate.